SC
TEVA icon

Stralem & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Stralem & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$2K Hold
149
– – ﹤0.01% 105
2020
Q1 		$1K Buy
+149
New +$1.53K ﹤0.01% 107

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Stralem & Co's TEVA Position: Q2 2020 in Review

Stralem & Co held its Teva Pharmaceuticals (TEVA) position steady in Q2 2020 at 149 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #105.

Stralem & Co first reported a position in TEVA in Q1 2020 and has held it in 2 quarters since. 456 funds tracked by Wall St. Rank hold TEVA as of Q2 2020.

  • Stralem & Co held 149 shares of Teva Pharmaceuticals worth $2K as of Q2 2020.
  • Stralem & Co left its Teva Pharmaceuticals share count unchanged in Q2 2020.
  • Teva Pharmaceuticals made up ﹤0.01% of Stralem & Co's portfolio in Q2 2020, its #105 holding.
  • Stralem & Co first reported a position in Teva Pharmaceuticals in Q1 2020 and has held it in 2 quarters since.
  • 456 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2020.

Based on Stralem & Co's 13F filing for Q2 2020, filed 20 Jul 2020.